Lakefront Biotherapeutics (GLPGF) Retained Earnings (2013 - 2025)

Lakefront Biotherapeutics (GLPGF) has reported Retained Earnings for 13 consecutive years, with $245.1 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Retained Earnings rose 270.79% year-over-year to $245.1 million in Q4 2025; TTM through Dec 2025 was $245.1 million, a 270.79% increase from a year earlier, with the FY2025 full-year figure at $237.9 million, up 263.67% from the prior year.
• Retained Earnings was $245.1 million for Q4 2025 at Lakefront Biotherapeutics, up from -$675.4 million in the prior quarter.
• Over five years, Retained Earnings peaked at $245.1 million in Q4 2025 and troughed at -$506.7 billion in Q4 2022.
• A 5-year average of -$66.5 billion and a median of -$413.3 million in 2022 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 270.79% in 2025, down 273.98% in 2025.
• Over 5 years, Retained Earnings stood at -$420.1 billion in 2021, then retreated by 20.63% to -$506.7 billion in 2022, then jumped by 99.95% to -$245.6 million in 2023, then surged by 41.57% to -$143.5 million in 2024, then soared by 270.79% to $245.1 million in 2025.
• The last three Retained Earnings figures came in at $245.1 million (Q4 2025), -$675.4 million (Q3 2025), and -$431.0 million (Q2 2025), per Business Quant data.